Cumberland Pharma Q3 net loss $1.5M; Caldolor study, DMD designations announced

CUMBERLAND PHARMACEUTICALS INC

2024-Q3 EPS reported -$0.32 revenue$27,432,376

Q3 2024 net revenue $9.1M; net loss $1.5M ($0.11 loss per share); adjusted loss $0.26M ($0.02 per share).
Real-world study of 150k patients shows Caldolor associated with fewer adverse drug reactions vs ketorolac.
FDA grants Orphan Drug and Rare Pediatric Disease designations for ifetroban in Duchenne Muscular Dystrophy.
Kristalose added to Medicaid plans in VA, LA, ME; Vibativ partner in Saudi Arabia begins ordering for launch.
Phase II MENDING trial for delirium meets primary safety endpoint; CET plans pivotal study discussion with FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.